Continuous Ambulatory Peritoneal Dialysis in Uremic Diabetics

  • Ramesh Khanna
  • Robert Mactier
  • Dimitrios Oreopoulos
Part of the Topics in Renal Medicine book series (TIRM, volume 6)

Abstract

In diabetic patients about to start dialysis for the first time, the attending physician should consider a number of medical and social factors before recommending continuous ambulatory peritoneal dialysis (CAPD). Because continuous dialysis therapy has such advantages as close control of blood sugar and ease of blood pressure control, some centers are recommending CAPD as the treatment of choice for diabetics needing dialysis.

Keywords

Peritoneal Dialysis Continuous Ambulatory Peritoneal Dialysis Osmotic Agent Chronic Peritoneal Dialysis Continuous Ambulatory Peritoneal Dialysis Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cardella CJ: Peritoneal dialysis and renal transplantation. Peritoneal Dial Bull 5: 149–151, 1985.Google Scholar
  2. 2.
    Khanna R, Oreopoulos DG: Peritoneal access for chronic peritoneal dialysis. Int J Artif Organs 8: 1–6, 1985.PubMedGoogle Scholar
  3. 3.
    Twardowski ZJ, Nolph KD, Khanna R, Prowant BF, Ryan LP, Nichols WK: The need for a “swan neck” permanently bent, arcuate peritoneal dialysis catheter. Peritoneal Dial Bull 5: 219–223, 1985.Google Scholar
  4. 4.
    Kim D, Burke D, Izatt S, Mathews R, Wu G, Khanna R, Vas S, Oreopoulos DG: Single or double-cuff peritoneal catheters? A prospective comparison. Trans Am Soc Artif Intern Organs 30: 232–235, 1984.PubMedGoogle Scholar
  5. 5.
    Perras ST, Zappacosta AR: Reduction of peritonitis with patient education and Travenol CAPD germicidal exchange system. American Nephrology Nurses Association 13: 219–222, 1986.Google Scholar
  6. 6.
    Hamilton RW: The sterile connection device: a review of its development and status report-1986. In: Khanna R, Nolph KD (eds) Advances in continuous ambulatory peritoneal dialysis 1986. Toronto: Peritoneal Dialysis Bulletin, 1986, pp 186–189.Google Scholar
  7. 7.
    Fenton SSA, Wu G, Bowman C, Cattran DC, Manuel A, Khanna R, Vas S, Oreopoulos DG: The reduction in the peritonitis rate among high-risk CAPD patients with the use of the Oreopoulos-Zellerman connector. Trans Am Soc Artif Intern Organs 31: 560–563, 1985.PubMedGoogle Scholar
  8. 8.
    Buoncristiani U, Quintaliani G, Cozzari M, Carobi C: Current status of the Y-set. In: Khanna R, Nolph KD, Prowant B, et al. (eds) Advances in continuous ambulatory peritoneal dialysis. Toronto: Peritoneal Dialysis Bulletin, 1986, pp 160–164.Google Scholar
  9. 9.
    Mistry CD, Mallick NP, Gokal R: The use of large molecular weight glucose polymer as an osmotic agent in CAPD. In: Khanna R, Nolph KD, Prowant B, et al. (eds) Advances in continuous ambulatory peritoneal dialysis. Toronto: Peritoneal Dialysis Bulletin, 1986, pp 7–11.Google Scholar
  10. 10.
    Matthys E, Dolkart R, Lameire N: Extended use of a glycerol containing dialysate in the treatment of diabetic CAPD patients. Peritoneal Dial Bull, 7: 10–15, 1987.Google Scholar
  11. 11.
    Bazato G, Coli U, Landini S: Zylitol and low doses of insulin: new perspectives for diabetic uremic patients on CAPD. Peritoneal Dial Bull 2: 161–164, 1982.Google Scholar
  12. 12.
    Twardowski ZJ, Khanna R, Nolph KD: Osmotic agents and ultrafiltration in peritoneal dialysis. Nephron 42: 93–101, 1986.PubMedCrossRefGoogle Scholar
  13. 13.
    Roscoe JM: Practices of insulin administration. Peritoneal Dial Bull 2: S27, 1982.Google Scholar
  14. 14.
    Felig P, Wahren J: The liver as site of insulin and glucagon action in normal, diabetic and obese humans. 1st J Med Sci 11: 528–539, 1975.Google Scholar
  15. 15.
    Greenwood RH, Davies CJ, Senator GB, O’Brien I, Hayes TM: The transport of peptide hormones across the peritoneal membrane in man. Clin Sci 57: 28–29, 1979.Google Scholar
  16. 16.
    Schades DS, Eaton RP: The peritoneum: a potential insulin delivery route for a mechanical pancreas. Diabetes Care 3: 229–234, 1980.Google Scholar
  17. 17.
    Rasio EA, Hampers CL, Soeldner JS, Cahill GF: Diffusion of glucose, insulin, inulin, and Evans blue protein into thoracic duct lymph of man. J Clin Investi 46: 903–910, 1967.CrossRefGoogle Scholar
  18. 18.
    Schade DS, Eaton RP, Davis T, Akiya F, Phinney E, Kubica R, Vaughn EA, Day PW: The kinetics of peritoneal insulin absorption. Metabolism 30: 149–155, 1981.PubMedCrossRefGoogle Scholar
  19. 19.
    Wideroe T, Smeby LC, Berg KJ, Jorstad S, Svartas TM: Intraperitoneal insulin absorption during intermittent and continuous peritoneal dialysis. Kidney Int 23: 22–28, 1983.PubMedCrossRefGoogle Scholar
  20. 20.
    Shapiro DJ, Blumenkrantz MJ, Levin SR, Coburn IW: Absorption and action of insulin added to peritoneal dialysate in dogs. Nephron 23: 174–180, 1979.PubMedCrossRefGoogle Scholar
  21. 21.
    Simon JD, Antoniades HN: Transport of peptide hormones across isolated rate mesentery: effect of human serum-bound insulin. Diabetes 24: 997–1004, 1975.PubMedCrossRefGoogle Scholar
  22. 22.
    Bracket E, Rasio E: The passage of 1251-insulin across isolated mesentery: effect of anti-insulin serum. Biochim Biophys Acta 183: 162–168; 1969.CrossRefGoogle Scholar
  23. 23.
    Stout RW: Diabetes and atherosclerosis: the role of insulin. Diabetologia 16: 141–150, 1979.PubMedCrossRefGoogle Scholar
  24. 24.
    Steinberg SM, Cutler SJ, Novak JW, Nolph KD: Characteristics of participants and selected outcome measures for the period Jan. 1981 through Aug. 1985. In: Report of the National CAPD Registry of the National Institutes of Health, Data Coordinating Center, Emes Corporation, Potomac, Maryland. 1986, pp 12–14.Google Scholar
  25. 25.
    Coheb IM: Diabetes, intraperitoneal insulin and CAPD Clin Exp Dial Apheresis 5: 269–275, 1981.Google Scholar
  26. 26.
    Amair P, Khanna R, Leibel B, Pierratos A, Vas S, Meema E, Blair G, Chisholm L, Vas M, Zingg W, Dibenis G, Oreopoulos D: Continuous ambulatory peritoneal dialysis in diabetics with end-stage renal disease. N Engl J Med 306: 625–630, 1982.PubMedCrossRefGoogle Scholar
  27. 27.
    Rubin J, Reed V, Adair C, Bower), Klein E: Effect of intraperitoneal insulin on solute kinetics in CAPD: insulin kinetics in CAPD. Am J Med Sci 291: 81–87, 1986.PubMedCrossRefGoogle Scholar
  28. 28.
    Madden MA, Zimmerman SW, Simpson DP: CAPD in diabetes mellitus: the risks and benefits of intraperitoneal insulin. Am J Nephrol 2: 133–139, 1982.PubMedCrossRefGoogle Scholar
  29. 29.
    Twardowski ZJ, Nolph KD, McGary TJ, Moore HL: Influence of temperature and time on insulin absorption to plastic bags. Am J Hosp Pharm 40: 583–586, 1983.PubMedGoogle Scholar
  30. 30.
    Vas SI: Peritonitis. In: Nolph KD (ed) Peritoneal dialysis. Boston: Martinus Nijhoff, 1985 pp 403–409.CrossRefGoogle Scholar
  31. 31.
    Rottembourg J, El Shahat Y, Agrafiotis A, Thuillier Y, De Groc F, Jacobs C, LeGrain M: Continuous ambulatory peritoneal dialysis in insulin-dependent diabetic patients: a 40 month experience. Kidney Int 23: 40–45, 1983.PubMedCrossRefGoogle Scholar
  32. 32.
    Henderson IS, Patterson KR, Leung ACT: Decreased intraperitoneal insulin requirements during peritonitis on continuous ambulatory peritoneal dialysis. Br Med J 290: 1474, 1985.CrossRefGoogle Scholar
  33. 33.
    Flynn CT, Nanson JA: Intraperitoneal insulin with CAPD: an artificial pancreas. Trans Am Soc Artif Intern Organs 25: 114–117, 1979.PubMedCrossRefGoogle Scholar
  34. 34.
    Balducci A, Slama G, Rottembourg J, Baumelou A, Delage A: Intraperitoneal insulin in uraemic diabetics undergoing CAPD. Br Med J 283: 1021–1023, 1981.CrossRefGoogle Scholar
  35. 35.
    Nolph KD, Stoltz M, Maher JF: Altered peritoneal permeability in patients with systemic vasculitis. Ann Intern Med 78: 891–894, 1973.PubMedGoogle Scholar
  36. 36.
    Khanna R, Wu G, Prowant B, Jastrzebska J, Nolph KD, Oreopoulos DG: CAPD in diabetics with ESRD: a combined experience of two North American centers. In: Friedman EA, L’Esperance FA Jr (eds) Diabetic renal-retinal syndrome. 3. New York: Grune and Stratton, 1986, pp 363–381.Google Scholar
  37. 37.
    Gilmore J, Wu G, Khanna R, Oreopoulos DG: Long-term CAPD. Peritoneal Dial Bull 5: 112–118, 1985.Google Scholar
  38. 38.
    Zimmerman SW, Johnson CA, O’Brien M: Survival of diabetic patients on CAPD for over five years. Perit Dial Bull (in press), 1987.Google Scholar
  39. 39.
    Katirtzoglou A, Izatt S, Oreopoulos DG: Chronic peritoneal dialysis in diabetics with ESRD. In: Friedman EA, L’Esperance FA Jr (eds) Diabetic renal-retinal syndrome. New York: Grune and Stratton, 1980, pp 317–332.Google Scholar
  40. 40.
    Report of the National CAPD Registry: A publication of the National CAPD Registry of the National Institute of Arthritis, Diabetes, and Digestive and Kidney Disease. Bethesda MD, 1986, pp 25–36.Google Scholar
  41. 41.
    Dombros N, Oren A, Marliss EB, Anderson GH, Stern AN, Khanna R, Pehl J, Brandes L, Roddella H, Labeil BS, Oreopoulos DG: Plasma amino acid profiles and amino acid losses in patients undergoing CAPD. Peritoneal Dial Bull 2: 27–32, 1982.Google Scholar
  42. 42.
    Giordano C, DeSanto NG, Capodicase G, et al.: Amino acid losses during CAPD. Clin Nephrol 14: 230–232, 1980.PubMedGoogle Scholar
  43. 43.
    Randerson D, Chapman GV, Farrel PC: Amino acid and dietary status in CAPD patients. In: Atkins RC, et al. (eds) Peritoneal dialysis. New York: 1981, Churchill Livingstone, pp 179–191.Google Scholar
  44. 44.
    Khanna R, Breckenridge C, Roncari D, Digenis G, Oreopoulos DG: Lipid abnormalities in patients undergoing continuous ambulatory peritoneal dialysis. Peritonteal Dial Bull 3: 13–15, 1983.Google Scholar
  45. 45.
    Faller B, Marichal JD: Loss of ultrafiltration in CAPD: clinical data. In: Gahl G, Kessel M, Nolph KD (eds) Advances in peritoneal dialysis. Amsterdam: Excerpta Medica, 1981, pp 227–232.Google Scholar
  46. 46.
    Slingeneyer A, Canaud B, Mion C: Permanent loss of ultrafiltration capacity of the peritoneum in long-term peritoneal dialysis. Nephron 33: 133–138, 1983.PubMedCrossRefGoogle Scholar
  47. 47.
    Shapiro FL, Comty CM: Hemodialysis in diabetics: 1981 In: Friedman EA, et al. (eds) Diabetic renal-retinal syndrome. New York: Grune and Stratton, 1982, pp 309–320.Google Scholar
  48. 48.
    Rottembourg J, Issad B, Poignet JL, et al.: Residual renal function and control of blood glucose levels in insulin-dependent diabetic patients treated by CAPD. In: Keen H, Legrain M (eds) Prevention and treatment of diabetic nephropathy. Boston: MTP Press, 1983, pp 339–352.Google Scholar
  49. 49.
    Khanna R, Wu G, Chisholm L, Oreopoulos DG: Further experience with CAPD in diabetics with end-stage renal disease. In: Keen H, Legrain M (eds) Prevention and treatment of diabetic nephropathy. Boston: MTP Press, 1983, pp 279–288.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1988

Authors and Affiliations

  • Ramesh Khanna
  • Robert Mactier
  • Dimitrios Oreopoulos

There are no affiliations available

Personalised recommendations